When in the course of diagnosis and history does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for identifying targeted therapies? How does NGS compare to hot spot testing?

When in the course of diagnosis and history does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for identifying targeted therapies? How does NGS compare to hot spot testing?

When exactly, in the course of a patient’s cancer diagnosis and history, does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for the purpose of identifying targeted therapies? And how do the capabilities of NGS compare to hot spot testing?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)

Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)

Medical Director & Consultant Medical Oncologist
The Cancer Centre (Singapore Medical Group)
Paragon Medical & Mt Elizabeth Novena
Specialist Centre Visiting Consultant
Mt Elizabeth Hospital & Mt Elizabeth Novena Hospital